A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy.

Trial Profile

A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Canagliflozin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CANTATA-SU
  • Sponsors Janssen Research & Development; Johnson & Johnson
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Dec 2016 Pooled analysis of 7 studies including this one and results of substudy of the CANVAS trial (n=432) were published in the Diabetes Therapy.
    • 16 Sep 2016 Results of a post-hoc analysis (n=1450) assessing the effects of Canagliflozin versus glimepiride on the components of metabolic syndrome, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top